TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04260438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501 0.5mg Tab. 1T, D759 100mg Tab. 1T and D150 1000mg Tab. 1T
Description: single oral administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501 0.5mg Tab. 1T, D759 100mg Tab. 1T and D150 1000mg Tab. 1T
Description: single oral administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501 0.5mg Tab. 1T, D759 100mg Tab. 1T and D150 1000mg Tab. 1T
Description: single oral administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501 0.5mg Tab. 1T, D759 100mg Tab. 1T and D150 1000mg Tab. 1T
Description: single oral administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-393 0.5/100/1000mg formulation 1 Tab. 1T
Description: single oral administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-393 0.5/100/1000mg formulation 1 Tab. 1T
Description: single oral administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-393 0.5/100/1000mg formulation 1 Tab. 1T
Description: single oral administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-393 0.5/100/1000mg formulation 1 Tab. 1T
Description: single oral administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-393 0.5/100/1000mg formulation 1 Tab. 1T
Description: single oral administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-393 0.5/100/1000mg formulation 1 Tab. 1T
Description: single oral administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-393 0.5/100/1000mg formulation 2 Tab. 1T
Description: single oral administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-393 0.5/100/1000mg formulation 2 Tab. 1T
Description: single oral administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-393 0.5/100/1000mg formulation 2 Tab. 1T
Description: single oral administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-393 0.5/100/1000mg formulation 2 Tab. 1T
Description: single oral administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-393 0.5/100/1000mg formulation 2 Tab. 1T
Description: single oral administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-393 0.5/100/1000mg formulation 2 Tab. 1T
Description: single oral administration under fed condition
Study: NCT02821052

Intervention type: DRUG
Intervention: insulin degludec/insulin aspart
Description: Enrolled patients will be treated with Ryzodeg® under routine clinical practice.
Study: NCT01682616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-199
Description: ABT-199 is taken continuously once daily. This is a dose escalation study, therefore the dose of ABT-199 will change throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be given by intravenous infusion on day 1 of Months 1, 2, 3, 4, 5, and 6. May be reinitiated for an additional 6 months.
Study: NCT03783273

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Single dose vitamin D3

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Single dose vitamin D3

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Single dose vitamin D3

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Single dose vitamin D3

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Whey protein-complex
Description: Whey protein complex-bound vitamin D3

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Water
Description: 500 mL water

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: 500 mL water

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Milk
Description: 500 mL milk

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Juice
Description: 500 mL juice

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Juice
Description: 500 mL juice
Study: NCT02766374

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart rate variability biofeedback
Description: Biofeedback teaches voluntary control of physiological functions by providing instantaneous feedback of variations in that bodily activity. Feedback usually is given in the form of visual and/or auditory signals derived from physiological recording devices. Among its salutary effects is a sense of medical self-efficacy, i.e., less dependency on medical professionals for maintaining personal health.~The HRV-BF protocol we have developed and propose to examine herein works by a different pathway. It involves teaching the individual to increase the amplitude of heart rate accelerations during inhalation and de-celerations during exhalation, thus increasing the amplitude of respiratory sinus arrhythmia (RSA).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The method consists of: 1) receiving EEG/music biofeedback (actually, a mildly relaxing intervention, using EEG biofeedback to alternately increase and decrease frontal/occipital EEG alpha rhythms while listening to relaxing music), and 2) listening to recorded sounds of nature along with relaxing music with instructions to maintain a condition of relaxed alertness. For home training, subjects will be given placebo StressEraser programmed to give feedback to maintain their breathing at baseline rate.
Study: NCT02546401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Aspart
Description: Injection of Insulin Aspart before or after meals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Aspart
Description: Injection of Insulin Aspart before or after meals
Study: NCT00687089

Intervention type: OTHER
Intervention: Sexual, cognitive functional tests and measurement weight
Study: NCT01760525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CGM097
Description: Patients treated with CGM097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CGM097
Description: Patients treated with CGM097
Study: NCT02874209

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sodium MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sodium MRI
Study: NCT04015323

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interferential current
Description: An electrotherapy current with different carrier frequencies

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interferential current
Description: An electrotherapy current with different carrier frequencies

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interferential current
Description: An electrotherapy current with different carrier frequencies
Study: NCT01709838

Intervention type: DRUG
Group type: OTHER
Intervention: deferasirox
Description: Deferasirox dispersible tablets at strengths of 125 mg, 250 mg, and 500 mg were administered by oral daily dosing.
Study: NCT02296021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berberine
Description: Berberine-containing quadruple therapy group: given for 14 days at a dose of berberine 100 mg 5 tablets BID, esomeprazole 20 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth
Description: Bismuth-containing quadruple therapy group: given for 14 days at a dose of colloidal bismuth tartrate capsule 55 mg 4 capsules BID, esomeprazole 20 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole
Description: Esmeprazole 20mg 1tablet BID plus amoxicillin 500 mg 2 capsules BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or berberine 100 mg 5 tablets BID as a dose given for bismuth-containing quadruple therapy or berberine-containing quadruple therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: esomeprazole
Description: Esmeprazole 20mg 1tablet BID plus amoxicillin 500 mg 2 capsules BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or berberine 100 mg 5 tablets BID as a dose given for bismuth-containing quadruple therapy or berberine-containing quadruple therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin
Description: Amoxicillin 500 mg 2 capsules BID plus esmeprazole 20mg 1tablet BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or berberine 100 mg 5 tablets BID as a dose given for bismuth-containing quadruple therapy or berberine-containing quadruple therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amoxicillin
Description: Amoxicillin 500 mg 2 capsules BID plus esmeprazole 20mg 1tablet BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or berberine 100 mg 5 tablets BID as a dose given for bismuth-containing quadruple therapy or berberine-containing quadruple therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clarithromycin
Description: Clarithromycin 500 mg 1 tablet BID plus amoxicillin 500 mg 2 capsules BID, esmeprazole 20mg 1tablet BID, and colloidal bismuth tartrate capsule55 mg 4 capsules BID or berberine 100 mg 5 tablets BID as a dose given for bismuth-containing quadruple therapy or berberine-containing quadruple therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clarithromycin
Description: Clarithromycin 500 mg 1 tablet BID plus amoxicillin 500 mg 2 capsules BID, esmeprazole 20mg 1tablet BID, and colloidal bismuth tartrate capsule55 mg 4 capsules BID or berberine 100 mg 5 tablets BID as a dose given for bismuth-containing quadruple therapy or berberine-containing quadruple therapy.
Study: NCT02871271

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IQP-AS-121
Study: NCT03378050

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HEART
Description: The intervention group will receive a multi-component individualized support intervention HEART, which will consist of 12 sessions in four stages. By using a comprehensive assessment targeting five components, an individualized intervention plan will be developed to address identified problems and unmet needs. Those five components consist of: Health, Emotion, Activities, Resources and Training.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Caregivers in the control group will receive 12 week follow-up as usual (FU) including two brief check-in calls and an outcome measures call during the study period.
Study: NCT04392583

Intervention type: DEVICE
Intervention: ENTACT Septal Staple system
Description: The ENTACT Septal Stapler delivers implantable septal staples which are intended to connect internal tissues to aid healing and for approximation of soft tissue during nasal septal surgery.
Study: NCT01164345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Plerixafor (mozobil) 240 mcg/kg SC will be administered in the evening, 10 hours prior to initiation of apheresis.G-CSF will be administered in the morning at 10 mcg/kg SC for 4 days prior to apheresis.
Study: NCT03720379

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fluor Protector S
Description: . All of the elements of a clinical trial and the varnish applications will be performed every three-month during one year: Changes in The Simplified Oral Hygiene Index (OHl-S), white spot carious lesion discovered at the initial assessment as invisible, visible and inactive, active, cavities), dmft and dmfs and their components, bite-wings and Diagnodent assessment will be scored at follow-up examinations.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All of the elements of a clinical trial and the placebo applications will be performed every three-month during one year: Changes in The Simplified Oral Hygiene Index (OHl-S), white spot carious lesion discovered at the initial assessment as invisible, visible and inactive, active, cavities), dmft and dmfs and their components, bite-wings and Diagnodent assessment will be scored at follow-up examinations.
Study: NCT02212288

Intervention type: OTHER
Intervention: Blood sample
Description: Blood samples are for metabolic and genetic and biological investigation

Intervention type: OTHER
Intervention: Blood sample
Description: Blood samples are for metabolic and genetic and biological investigation

Intervention type: OTHER
Intervention: Urine sample
Description: Urine sample for biological investigation

Intervention type: OTHER
Intervention: Urine sample
Description: Urine sample for biological investigation
Study: NCT00281671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nesiritide
Description: nesiritide 0.015 mcg/kg/hour x 10 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride infusion
Study: NCT02203422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporin A
Description: given orally at a dose of 1.5-2.0mg/kg twice daily for 3 consecutive months, adjusted to maintain serum levels between 200-400 ng/ml and tapered by 50 mg/d per week if patients achieved a complete response.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporin A
Description: given orally at a dose of 1.5-2.0mg/kg twice daily for 3 consecutive months, adjusted to maintain serum levels between 200-400 ng/ml and tapered by 50 mg/d per week if patients achieved a complete response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhTPO
Description: given subcutaneously at a dose of 300 Units/kg for 14 consecutive days, following with a flexible dosage depending on platelet count until the 29th day
Study: NCT00593489

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Basal Insulin Initiation Strategy
Description: This multifaceted intervention consists of (1) Diabetes Specialist Consultation Support which entails specialists and educators providing consultation for insulin initiation and titration for the 12 months following the Workshop. Support will consist of prearranged and scheduled communications to review and advise for the first 2 months and will continue on an ad hoc basis for the remaining 10 months, with communication initiated by the physician (2)Community Pharmacy Insulin Initiation consists of trained community pharmacists providing patient education insulin initiation. Education will consist of one individual teaching session, one hour in duration, to review the insulin prescription protocol, insulin injection method, management of hypoglycemia, and self-monitoring of blood glucose.
Study: NCT02131597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guadecitabine
Description: Given SC
Study: NCT02646930

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial biopsy
Description: Endometrial biopsy in women undergoing first IVF cycle
Study: NCT03591393

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: questionnaire
Description: Validated self-administered questionnaires with five domains: Wexner questionnaire for anal incontinence, PAC-SYM for constipation, International Consultation on Incontinence Questionnaire Short Form for urinary incontinence, the Pelvic Organ Prolapse Distress Inventory for pelvic organ prolapse, POP/UI Sexual Questionnaire - IUGA revised for sexual function.~The body image perception will be assessed using the Dutch-validated version of the self-administered Body Image Disturbance Questionnaire.
Study: NCT01413516

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking cessation counseling
Description: Counseling sessions provided by a trained smoking counselor

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Smoking cessation counseling
Description: Counseling sessions provided by a trained smoking counselor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill without any active medication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Varenicline (an approved medication for smoking cessation)
Study: NCT03452332

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Undergo SABR

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Given IV
Study: NCT03762486

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: 4 electrodes were placed 2-3 cm lateral to the incision of the patients at the 30th minute and 2, 18, 22, 42, and 46th hours after the surgery and electrical stimulation was implemented at varying frequencies of 2-100 Hz for 30 minutes, at a maximum current intensity of 12 milliamperes that would not bother the patient or create muscle contractions, with a pulse duration of 0.25 min

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TAES
Description: 4 electrodes were placed at the ST25, P6, ST36, and LI4 acupuncture points of the patients at the 30th minute and 2, 18, 22, 42, and 46th hours after the surgery and electrical stimulation was implemented at varying frequencies of 2-100 Hz for 30 minutes, at a maximum current intensity of 12 milliamperes that would not bother the patient or create muscle contractions, with a pulse duration of 0.25 min
Study: NCT00003521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Patients with Soft Tissue Sarcoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT06180265

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: presepsin, procalciton, endotoxin
Description: measurement of presepsin, procalciton, endotoxin plasmatic levels
Study: NCT03562741

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Transplantation of Screened donor stool as part of Fecal Microbiota Transplantation
Study: NCT00324480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT01922882

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Amagugu Counseling Intervention
Description: 6-session home-based counseling intervention delivered by lay counselors at mothers' homes
Study: NCT00003935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT05522283

Intervention type: DIAGNOSTIC_TEST
Intervention: Stool and blood CMV PCR
Description: Quantitative stool CMV-PCR (CMV R-gene® kit, limit of detection 450 copies/ml, Biomerieux, France) and quantitative serum CMV-PCR (Cobas® CMV, limit of detection 150 copies/ml, Roche, USA) were collected within seven days of colonoscopy.

Intervention type: DIAGNOSTIC_TEST
Intervention: Stool and blood CMV PCR
Description: Quantitative stool CMV-PCR (CMV R-gene® kit, limit of detection 450 copies/ml, Biomerieux, France) and quantitative serum CMV-PCR (Cobas® CMV, limit of detection 150 copies/ml, Roche, USA) were collected within seven days of colonoscopy.

Intervention type: DIAGNOSTIC_TEST
Intervention: Stool and blood CMV PCR
Description: Quantitative stool CMV-PCR (CMV R-gene® kit, limit of detection 450 copies/ml, Biomerieux, France) and quantitative serum CMV-PCR (Cobas® CMV, limit of detection 150 copies/ml, Roche, USA) were collected within seven days of colonoscopy.
Study: NCT01656707

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACRA
Description: Ten weekly,60-minute therapy sessions including six individual, two parent/guardian and two joint (individual and parent/guardian).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT
Description: 10 weekly, 60-minute sessions of augmented individualized CBT
Study: NCT01618240

Intervention type: OTHER
Intervention: Muscle Strength Measurement
Description: MRC score (0-60) is a clinical assessment of muscle power on abduction of the arm, flexion of the forearm, extension of the wrist, flexion of the leg, extension of the knee and dorsal flexion of the foot with the score of (0-5) on each measurement

Intervention type: OTHER
Intervention: Ventilator
Description: A mechanical ventilator is used to assist or replace spontaneous breathing.
Study: NCT04035343

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Face down positioning
Description: See description of the face down positioning group

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supine positioning
Description: See description of the supine positioning group
Study: NCT02811120

Intervention type: OTHER
Intervention: venepuncture only
Description: single venepuncture
Study: NCT02054039

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Incentive spirometry (IS)
Description: Mechanical devices activated by an inspiratory effort, which is viewed by the elevation of a plateau or balls in a transparent cylinder having a calibrated scale that displays the inspired flow.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Breath Stacking (BS)
Description: Equipment with a one-way valve that masks and promotes the accumulation of successive inspiratory volumes, preventing expiration
Study: NCT00069836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone/metformin
Study: NCT01860911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NG-monomethyl-L-arginine
Study: NCT03247517

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was administered once daily
Study: NCT03108703

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: 35-40 Gy delivered in 5 fractions